Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-7.32%
-1.99%
+0.14%
-3.06%
LH
Laboratory Corporati
$279.44
Login to see Laboratory Corporati (LH) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Trading below its fair value
Chart
$278.11 (+0.48%)
$249.62 (+11.95%)
$243.44 (+14.79%)
$220.51 (+26.72%)
LH has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
LH overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
LH Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
LH Street view is extremely bullish and have positive views on the near-term outlook
LH Earnings
The TTM reflects 12-month period, providing review of LH financial performance.
The company financial health has moderately improved over the past year
Financial Score
What is LH current stock price?
What are LH stock strengths?
What risks are associated with LH stock?
When is LH next earnings report?
What is LH market cap and volume?
What is LH's current Stock IQ?
Should I buy LH stock right now?
Is LH a Strong Buy right now?
What does a 'Strong Buy' rating mean for LH?
What does a 'Strong Sell' rating mean for LH?
What factors influence LH's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.32%
-1.99%
+0.14%
-3.06%
LH
Laboratory Corporati
Current Price
$279.44
Stock Insights
Strengths
Earnings are forecast to grow
Trading below its fair value
Login to unlock Laboratory Corporati (LH) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$278.11 (+0.48%)
$249.62 (+11.95%)
$243.44 (+14.79%)
$220.51 (+26.72%)
LH Analysts Opinion
LH Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
LH Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
LH Street view is extremely bullish and have positive views on the near-term outlook
LH has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
LH Earnings
The TTM data reflects the most recent 12-month period, providing overview of LH financial performance.
LH Financial Health
The company financial health has moderately improved over the past year
Financial Score
LH Latest Analysis
LEXX: Biodistribution Study Results . By As we step into fall Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this week. Activity in the obesity and GLP-1 agonist space has been robust in 2025 with a number of deals and new trial data announced. In th
Today
Rock Tech and ArcelorMittal Agree on Cooperation to Strengthen Regional Industrial Competence. Rock Tech Guben GmbH and ArcelorMittal Eisenhüttenstadt GmbH have signed a letter of intent to intensify regional synergies in industry in East Brandenburg.The main focus lies on joint efforts in securing and qualifying skilled workers as well as collaboration in laboratory services and quality assurance.Further cooperation areas are being evaluated by both companies including local services and rail l
Today
COPPER GIANT ACHIEVES UP TO 92% COPPER AND 97% MOLYBDENUM RECOVERIES IN LATEST METALLURGICAL TESTWORK AT MOCOA. Initial bench-scale rougher flotation laboratory test results show strong recoveries — up to 92% copper and 97% molybdenum exceeding the assumptions (90% Cu 75% Mo) used in the current resource model.Grind sizes were relatively coarse with a P80 150–180μm in TIMA analysis. Molybdenum mineralogical analysis shows 97% of molybdenite reported as free grains at P80 150–180μm in TIMA-X (TES
Today
AIxMed and Biopticka Laboratoř Announce Strategic Collaboration to Advance AI-Powered Cytology in Europe. SANTA CLARA Calif. Oct. 2 2025 /PRNewswire/ -- AIxMed Inc. a leader in computational cytology and AI-powered diagnostics and Biopticka Laboratoř s.r.o. the Czech Republics leading private reference laboratory today announced the signing of a Memorandum of Understanding (MOU) to...
Today
Global Companion Diagnostics Market to Surpass USD 13.6 Billion by 2029 | MarketsandMarkets™. Delray Beach FL Sept. 30 2025 (GLOBE NEWSWIRE) -- The global companion diagnostics market valued at US$6.8 billion in 2023 stood at US$7.5 billion in 2024 and is projected to advance at a resilient CAGR of 12.6% from 2024 to 2029 culminating in a forecasted valuation of US$13.6 billion by the end of the period. This growth underscores the increasing role of precision medicine in reshaping modern healthc
Tue Sep 30, 2025
Copan Expands United States Manufacturing Footprint with Multimillion-Dollar Investment. MURRIETA Calif. Sept. 24 2025 /PRNewswire/ -- Copan Diagnostics part of the privately held Italy-based Copan Group and a leader in specimen collection and transport and laboratory automation announced over $7 million in new United States manufacturing investments in California and Puerto...
Wed Sep 24, 2025
Fireweed Intersects 30 m True Width of 33.2% Zinc Equivalent in 115 m Step-Out at Tom South. TSXV: FWZOTCQX: FWEDFFSE: M0GFireweed". or the ".Company".) (TSXV:) (OTCQX:) is pleased to report the results of the first drill holes from the Tom deposit that intersected high-grade zinc-lead-silver (".Zn-Pb-Ag".) mineralization as part of the 2025 drill campaign at its Macpass Project (".Macpass".) HighlightsA major Hole TS25-001D1: 1 (".ZnEq".) ( ( ( (Alongside the critical
Wed Sep 24, 2025
Prudent Investors Concerned About Extreme Euphoria Represented by Oklo Rally And Impact Of Trumps $100K Visas On Mag 7.
Mon Sep 22, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings